Tri-Tech Biopharm

Tri-Tech Biopharm is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of innovative drug delivery systems for macromolecular therapeutics. The company utilizes its proprietary Oral-Trans platform to convert injectable peptides and proteins into oral dosage forms, significantly enhancing patient convenience and adherence. Its primary research focus is on metabolic disorders, with a pipeline featuring oral insulin and GLP-1 receptor agonists. Tri-Tech Biopharm's technology addresses the physiological barriers of the gastrointestinal tract to ensure effective absorption of complex biologics. The company maintains its own research and development facilities to advance its portfolio of non-invasive treatment options.